Trulicity

Description

Trulicity (dulaglutide) is a medication classified as a GLP-1 receptor agonist, used to manage type 2 diabetes. By binding to GLP-1 receptors, Trulicity stimulates an increase in cyclic AMP (cAMP) within pancreatic beta cells. This biochemical reaction promotes the release of insulin in a glucose-dependent manner, meaning insulin is released more when blood glucose levels are high. This action helps reduce blood sugar levels after meals.

In addition to stimulating insulin release, Trulicity decreases glucagon secretion from pancreatic alpha cells. Glucagon usually raises blood sugar levels, so reducing its release further helps maintain steady blood sugar levels. Trulicity also slows the emptying of the stomach, which can prevent sudden spikes in blood glucose after eating. By delaying gastric emptying, Trulicity promotes a feeling of fullness, which may help reduce overall food intake.

Trulicity is available as a solution specifically designed for subcutaneous injection. It comes in prefilled, single-use pens for ease of administration. The initial recommended dose for most adults is 0.75 mg, given once weekly. For patients requiring greater blood sugar control, the dose can be increased to 1.5 mg, then to 3.0 mg, and up to a maximum of 4.5 mg once weekly.

Trulicity can be administered at any time of the day, without regard to meals. The injection should be given subcutaneously in one of three recommended areas: the abdomen, thigh, or upper arm. When injecting, patients should rotate the injection sites each week to avoid irritation.